All Phenotypes Tg(tetO-Nras*Q61K)#Lc MGI Mouse

integument

increased cutaneous melanoma incidence ( J:238049 )

• mice administered doxycycline at weaning develop spontaneous melanoma after an average of 15 weeks with a 50% penetrance

• withdrawal of doxycycline results in rapid, durable and complete tumor regression within 10 days

• doxycycline treated mice administered the MEK inhibitor Selumetinib or GSK1120212 show tumor stasis but not tumor regression

• doxycycline treated mice administered a selective inhibitor of CDK4/6, PD-0332991 together with either Selumetinib or GSK1120212 show tumor regression

neoplasm

increased cutaneous melanoma incidence ( J:238049 )

• mice administered doxycycline at weaning develop spontaneous melanoma after an average of 15 weeks with a 50% penetrance

• withdrawal of doxycycline results in rapid, durable and complete tumor regression within 10 days

• doxycycline treated mice administered the MEK inhibitor Selumetinib or GSK1120212 show tumor stasis but not tumor regression

• doxycycline treated mice administered a selective inhibitor of CDK4/6, PD-0332991 together with either Selumetinib or GSK1120212 show tumor regression

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 08/21/2024 MGI 6.24